Yue Huang
Kunming Medical University, Kunming 650500, Yunnan Province, China; Department of Ophthalmology, Yunnan University Affiliated Hospital, Kunming 650000, Yunnan Province, ChinaYan Li
Department of Ophthalmology, Yunnan University Affiliated Hospital, Kunming 650000, Yunnan Province, ChinaZheng-Yi-Lin Bao
Kunming Medical University, Kunming 650500, Yunnan Province, China; Department of Ophthalmology, Yunnan University Affiliated Hospital, Kunming 650000, Yunnan Province, ChinaYu-Ting Li
Department of Ophthalmology, Yunnan University Affiliated Hospital, Kunming 650000, Yunnan Province, ChinaYong-Yuan Yu
Kunming Medical University, Kunming 650500, Yunnan Province, ChinaZhu-Lin Hu
Department of Ophthalmology, Yunnan University Affiliated Hospital, Kunming 650000, Yunnan Province, ChinaScience and Technology Plan Project of Yunnan Provincial Department of Science and Technology(No.202201AT070073); Yunnan Basic Research Special Project Kunming Medical Union Special Project(No.202001AY070001-165)
Pseudoexfoliative glaucoma(PEXG)is an eye disease that seriously endangers vision. It is more invasive than primary open-angle glaucoma(POAG), with more serious damage to the optic nerve, worse prognosis and higher resistance to treatment. Early diagnosis of PEXG can help to treat the disease in time and delay the progress of the disease, so it is important to determine appropriate biomarkers. In recent years, more and more people have begun to study the biomarkers of PEXG, hoping to understand the pathogenesis of the disease, find out the potential early diagnosis and treatment targets of PEXG, and provide some help to the disease through the research of genomics, transcriptomics, proteomics, metabolomics and lipomics markers. This article will review the progress of biomarkers of PEXG in recent years, some biomarkers may provide new ideas for early diagnosis of PEXG in the future.
Yue Huang, Yan Li, Zheng-Yi-Lin Bao,/et al.Research progress on biomarkers of pseudoexfoliative glaucoma. Guoji Yanke Zazhi( Int Eye Sci) 2023;23(7):1134-1138
Copy